Abstract: The present invention relates to a conjugate for preventing and treating viral infections and a use thereof, and in particular, to a protein-anti-influenza compound conjugate having a structure of formula I-1 or a pharmaceutically acceptable salt, an ester, an isomer, a solvate, a prodrug or an isotope label thereof. The conjugate has small molecules (D1 and D2) linked, by means of linkers (L1 and L2) to an Fc monomer, an Fc domain, an Fc linker peptide, an albumin or an albumin linker peptide (E) and having anti-influenza virus activity. The conjugate or the intermediate compound of the present invention has significant anti-influenza virus activity, and meanwhile, has excellent in vitro/in vivo pharmacokinetic property and safety and has good clinical application prospects.

Abstract: The invention provides compounds represented by the formula I, each of which compounds may have sphingosine-1-phosphate receptor agonist and or antagonist biological activity: and wherein the variables Y, R4, n, o, A, A1, A2, X, Z, R1, R3, R2, p, q and r are as defined in the specification.

Abstract: The invention provides compounds represented by the formula I, each of which compounds may have sphingosine-1-phosphate receptor agonist and or antagonist biological activity: and wherein the variables Y, R4, n, o, A, A1, A2, X, Z, R1, R3, R2, p, q and r are as defined in the specification.